HAVCR2 and acute myeloid leukemia: We assessed the TIM-3 expression on leukemic blasts of 34 patients diagnosed with de novo AML (except for M3) using flow cytometry, and the percentage of TIM-3 expression ranged from 0 to 68.43%.